FDA approves treatment for common gynecologic infection: 3 things to know

Symbiomix Therapeutics on Monday earned Food and Drug Administration approval for its antibiotic Solosec.

Here are three things to know.

1. The single dose antibiotic is intended to treat bacterial vaginosis, the most common gynecologic infection in the country.

2. Solosec is the first oral antibiotic approved for the infection in more than a decade.

3. Symbiomix expects the drug to hit the market in the first quarter of 2018.

More articles on supply chain:

NIH issues $15M in grants for development of 3-D human tissue models
Biosimilars are getting approved, but few have hit the market — here's why
6 drugmakers in the headlines

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers